In glioblastoma, GBP1 acts as an EGFR-induced effector, enhancing tumor growth in vivo—an effect absent in vitro, suggesting reliance on stromal or immune interactions within the brain tumor microenvironment (TME) [17]. Here, GBP1 is linked to neoplasm.